Elsevier

Neuropharmacology

Volume 196, 15 September 2021, 108684
Neuropharmacology

Female but not male rats show biphasic effects of low doses of Δ9-tetrahydrocannabinol on anxiety: can cannabidiol interfere with these effects?

https://doi.org/10.1016/j.neuropharm.2021.108684Get rights and content

Highlights

  • THC produced biphasic effects on anxiety in females.

  • The same dose range of THC induced no anxiety changes in males.

  • Increased mPFC and NAc dopamine content accompanied the THC anxiogenic dose.

  • Increased mPFC serotonin content accompanied the THC anxiolytic dose.

  • CBD enhanced the anxiolytic effect of THC and abolished its anxiogenic effect.

Abstract

Δ9-tetrahydrocannabinol (THC) is the main phytocannabinoid present in the Cannabis sativa. It can produce dose-dependent anxiolytic or anxiogenic effects in males. THC effects on anxiety have scarcely been studied in females, despite their higher prevalence of anxiety disorders. Cannabidiol, another phytocannabinoid, has been reported to attenuate anxiety and some THC-induced effects. The present study aimed to investigate the behavioral and neurochemical effects of THC administered alone or combined with CBD in naturally cycling female rats tested in the elevated plus-maze. Systemically administered THC produced biphasic effects in females, anxiolytic at low doses (0.075 or 0.1 mg/kg) and anxiogenic at a higher dose (1.0 mg/kg). No anxiety changes were observed in males treated with the same THC dose range. The anxiogenic effect of THC was prevented by co-administration of CBD (1.0 or 3.0 mg/kg). CBD (3.0 mg/kg) caused an anxiolytic effect. At a lower dose (1.0 mg/kg), it facilitated the anxiolytic effect of the low THC dose. The anxiogenic effect of THC was accompanied by increased dopamine levels in the medial prefrontal cortex (mPFC) and nucleus accumbens (NAc). In contrast, its anxiolytic effect was associated with increased mPFC serotonin concentrations. The anxiolytic effect of CBD was accompanied by increased mPFC serotonin turnover. Together, these results indicate that female rats are susceptible to the biphasic effects of low THC doses on anxiety. These effects could depend on mPFC and NAc dopaminergic and serotoninergic neurotransmissions. CBD could minimize potential THC high-dose side effects whereas enhancing the anxiolytic action of its low doses in females.

Introduction

Cannabis is still considered an illicit drug, even though its medicinal use has increased over the last few years. Among cannabis active compounds, cannabidiol (CBD) is the most studied due to its safety profile and therapeutic potential for several diseases (Bitencourt et al., 2021; Melas et al., 2021; Peters et al., 2021; Stern et al., 2018). On the other hand, Δ9-tetrahydrocannabinol (THC) is the primary psychoactive component responsible for cannabis recreational and undesirable clinical effects. However, THC is present in several medicinal preparations alone or combined with CBD (Freeman et al., 2019). Synthetic THC (dronabinol) is approved for nausea and vomiting in patients undergoing chemotherapy (Serafimovska et al., 2020). Sativex®, which contains a ratio of ~1:1 of THC and CBD, is approved for multiple sclerosis spasticity at doses varying from 1.0 to 20 mg (MacCallum and Russo, 2018). Considering that high doses of THC potentially produce undesirable effects, some authors have addressed the importance of using low to ultra-low doses of THC. In this line, low doses of THC reverse cognitive impairment in old mice (Bilkei-Gorzo et al., 2017), also, ultra-low doses of THC improved cognitive performance in a spatial memory test in old female mice (Sarne et al., 2018) and did not affect anxiety (Fishbein-Kaminietsky et al., 2014), an undesirable effect of THC.

Anxiety disorders have a higher prevalence in women (Marvaldi et al., 2021). Sexual dimorphism is a relevant factor that interferes with mood, including anxiety-like behaviors, and increases susceptibility to a stressful stimulus (Altemus et al., 2014; Shansky et al., 2004). Besides, evidence suggests that females are more sensitive to Cannabis effects than males (Cooper and Craft, 2018). In line with this, developmental exposure to CBD increased anxiety in female offspring, but not males (Wanner et al., 2021). Treatment with 5.0 mg/kg of THC increased only the female rats’ avoidance in the open-field test and c-Fos expression in stress-related brain areas (Ruiz et al., 2021). However, others have shown that the anxiogenic effect of high doses of THC is observed in both male and female mice (Bruijnzeel et al., 2019; Kasten et al., 2019). Thus, the available preclinical data vary widely in dosage and evaluate the effects of conventional and high THC doses on anxiety. Identifying the acute effects of lower doses of THC and THC combined with CBD on anxiety in females is necessary for developing appropriate cannabis-based treatments.

The serotoninergic and dopaminergic transmissions in the medial prefrontal cortex (mPFC) and nucleus accumbens (NAc) are essential to regulate anxiety and motivated behaviors in rodents and humans (Everett et al., 2021; Liu et al., 2019; Marcus et al., 2020; Stern et al., 2010). CBD and THC interact with multiple targets, including serotonin 5-HT1A receptors (Campos et al., 2012; Raymundi et al., 2020a; O'Sullivan and Kendall et al., 2010). Chronic treatment with THC 1.0 mg/kg in adolescent rats reduced the dorsal raphe nucleus's neural activity, and knockout mice for the 5-HT2A receptor were insensitive to the anxiolytic effects of a low THC dose (De Gregorio et al., 2020; Viñals et al., 2015). Regarding the dopaminergic neurotransmission, enhancing endocannabinoid transmission in the ventral tegmental area (VTA) abolished the avoidance behavior induced by reducing dopamine release. Systemic administration of the CB1/CB2 agonist WINN55,212–2 increased neuronal activity in the VTA and dopamine efflux in the NAc (Cheer et al., 2004; Wenzel and cheer, 2018).

Considering the increasing use of medicinal cannabis preparations containing THC alone or THC and CBD combined in different proportions, and the lack of studies investigating the effects of THC and THC plus CBD in female rats, this study aimed to investigate the effects of low doses of THC alone and combined with CBD on anxiety-like behavior in male and female rats exposed to the elevated plus-maze (EPM). In part of these animals, we also analyzed the serotoninergic and dopaminergic contents in the mPFC and NAc. The results showed that females are more sensitive to the effects of low THC doses on anxiety than males. CBD potentiated the anxiolytic and abolished the anxiogenic effect of THC. The anxiogenic effect of THC was associated with increased mPFC and NAc dopamine levels, whereas increased mPFC serotonin accompanied the THC anxiolytic effect.

Section snippets

Animals

Three months-old female and male Wistar rats weighing 230–300 g were used in the present work. The animals were obtained from the local vivarium and housed in groups of 4–5 per cage (50 × 30 × 15 cm), under light: dark cycle of 12 h (beginning of the light phase at 7:00 h), in a temperature-controlled room (22 ± 1 °C), with access to food and water ad libitum for at least seven days before testing. The experimental protocols were approved by the Ethics Committee for the use of animals in the

Experiment 1: effects of THC in female rats tested in the EPM

Fifty animals were randomly allocated to four groups (n = 12–13/group) based on the treatment (vehicle, 0.075, 0.1, or 1.0 mg/kg of THC) administered 20 min before the EPM testing.

One-way ANOVA showed significant treatment effects for %OAT [F(3,46) = 23.4; p = 0.000001; η2 = 0.60] and %OAE [F(3,46) = 13.0; p = 0.000001; η2 = 0.46], but not EAE [F(3,46) = 0.80; p = 0.50; η2 = 0.05]. Newman-Keuls post-hoc tests showed that animals treated with THC 1.0 mg/kg presented lower %OAT (p = 0.0001; Fig. 2

Discussion

Female rats systemically treated with THC 0.075 or 0.1 mg/kg showed enhanced open arms exploration compared to controls, suggesting an anxiolytic-like effect. This result agrees with that reported in male rats and mice tested in the EPM (Onaivi et al., 1990; Braida et al., 2007; Rubino et al., 2007), and other anxiety tests (e.g., Berrendero and Maldonado, 2002), although the most effective dose was usually higher in those studies. In contrast, a higher dose of THC (1.0 mg/kg) decreased open

Conclusions

The present work reports differences in the sensitivity to THC effects on anxiety between male and female rats, suggesting that females would benefit from lower doses of THC. CBD potentiated the anxiolytic-like effect of a low THC dose, suggesting an additive/synergic action. It also prevented the anxiogenic effects of a higher THC dose, supporting the proposal that it could counteract the potential unwanted effects of THC. THC and CBD effects could be associated with changes in dopamine and

Author contribution

CAJS: Conceptualization, designed and performed the experiments, Formal analysis and Data curation, Project administration and Resources, Writing – review & editing, Writing – original draft and final revision and editing of the manuscript. AMR: Conceptualization, designed and performed the experiments, Formal analysis and Data curation, Writing – review & editing, Writing – original draft and final revision and editing of the manuscript. BZS: Conceptualization, designed and performed the

Role of funding source

Our study was supported by Brazilian grants from Fundação Araucária (convênio 043/2020), Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP; 2017/24,304–0), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; 409,255/2018–1) and by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brazil (CAPES) - Finance Code 001. Fundação Araucária, CNPq and CAPES had no further role in study design; in the collection, analysis and interpretation of data; in the

Declaration of competing interest

FSG is a co-inventor (Mechoulam R, JC, Guimaraes FS, AZ, JH, Breuer A) of the patent “Fluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO/2014/108,899. International Application No.: PCT/IL 2014/050,023″ Def. US no. Reg. 62193296; July 29, 2015; INPI on August 19, 2015 (BR1120150164927). The University of São Paulo has licensed the patent to Phytecs Pharm (USP Resolution No. 15.1.130002.1.1). The University of São Paulo has an agreement with Prati-Donaduzzi (Toledo, Brazil)

Acknowledgements

We thank Gisele Oliveira Guaita, from the Department of Pharmacology, UFPR, for her technical support on the neurochemical analysis. We thank HempMeds® Brazil for kindly donating the CBD and Aura Pharma, Uruguay, for kindly donating the THC.

References (91)

  • E. Galaj et al.

    Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT1A and TRPV1 receptor mechanisms

    Neuropharmacology

    (2020)
  • S.E. Gartside et al.

    Neurochemical and electrophysiological studies on the functional significance of burst firing in serotonergic neurons

    Neuroscience

    (2000)
  • N.C. Glodosky et al.

    Cannabis vapor self-administration elicits sex- and dose-specific alterations in stress reactivity in rats

    Neurobiol. Stress.

    (2020)
  • F.S. Guimarães et al.

    Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze

    Gen. Pharmacol.

    (1994)
  • J.T. Imhof et al.

    Influence of gender and age on performance of rats in the elevated plus maze apparatus

    Behav. Brain Res.

    (1993)
  • J.I. Lemos et al.

    Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats

    Behav. Brain Res.

    (2010)
  • L. Liu et al.

    Dopamine D1 receptor in the medial prefrontal cortex mediates anxiety-like behaviors induced by blocking glutamatergic activity of the ventral hippocampus in rats

    Brain Res.

    (2019)
  • D.T. Malone et al.

    Cannabidiol reverses the reduction in social interaction produced by low dose Δ9-tetrahydrocannabinol in rats

    Pharmacol. Biochem. Behav.

    (2009)
  • A.L. Marinho et al.

    Effects of intra-infralimbic prefrontal cortex injections of cannabidiol in the modulation of emotional behaviors in rats: contribution of 5HT₁A receptors and stressful experiences

    Behav. Brain Res.

    (2015)
  • M. Marvaldi et al.

    Anxiety, depression, trauma-related, and sleep disorders among healthcare workers during the COVID-19 pandemic: a systematic review and meta-analysis

    Neurosci. Biobehav. Rev.

    (2021)
  • S.E. O'Sullivan et al.

    Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease

    Immunobiology

    (2010)
  • C.J. Riebe et al.

    Estrogenic regulation of limbic cannabinoid receptor binding

    Psychoneuroendocrinology

    (2010)
  • K. Sano et al.

    D9-Tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons

    Neuroscience

    (2008)
  • Y. Sarne et al.

    Reversal of age-related cognitive impairments in mice by an extremely low dose of tetrahydrocannabinol

    Neurobiol. Aging

    (2018)
  • A.P. Schiavon et al.

    Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice

    Prog. Neuro-Psychopharmacol. Biol. Psychiatry

    (2016)
  • J. Solati et al.

    5HT 1A and 5HT 1B receptors of medial prefrontal cortex modulate anxiogenic-like behaviors in rats

    Neurosci. Lett.

    (2011)
  • C.A. Stern et al.

    Activity in prelimbic cortex is required for adjusting the anxiety response level during the elevated plus-maze retest

    Neuroscience

    (2010)
  • C.A. Stern et al.

    Δ9-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption

    Eur. Neuropsychopharmacol

    (2015)
  • H.J. Szkudlarek et al.

    THC and CBD produce divergent effects on perception and panic behaviours via distinct cortical molecular pathways

    Prog. Neuro-Psychopharmacol. Biol. Psychiatry

    (2021)
  • A.H. Tseng et al.

    Pharmacokinetic factors in sex differences in Delta 9-tetrahydrocannabinol-induced behavioral effects in rats

    Behav. Brain Res.

    (2004)
  • F. Vergara et al.

    Contribution of mesolimbic dopamine and kappa opioid systems to the transition from acute to chronic pain

    Neuropharmacology

    (2020)
  • A.A. Wakley et al.

    Sex differences in antinociceptive tolerance to delta-9-tetrahydrocannabinol in the rat

    Drug Alcohol Depend.

    (2014)
  • J.L. Wiley et al.

    Comparison of the discriminative stimulus and response rate effects of Δ9-tetrahydrocannabinol and synthetic cannabinoids in female and male rats

    Drug Alcohol Depend.

    (2017)
  • J.L. Wiley et al.

    Sex, species and age: effects of rodent demographics on the pharmacology of Δ9-tetrahydrocanabinol

    Prog. Neuro-Psychopharmacol. Biol. Psychiatry

    (2021)
  • J.C. Arnold et al.

    The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia

    Curr. Pharmaceut. Des.

    (2012)
  • D. Baker-Andresen et al.

    Activation of BDNF signaling prevents the return of fear in female mice

    Learn. Mem.

    (2013)
  • F.R. Bambico et al.

    Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex

    J. Neurosci.

    (2007)
  • J.B. Becker et al.

    Strategies and methods for research on sex differences in brain and behavior

    Endocrinology

    (2005)
  • F. Berrendero et al.

    Involvement of the opioid system in the anxiolytic-like effects induced by Δ9-tetrahydrocannabinol

    Psychopharmacology (Berl)

    (2002)
  • A. Bilkei-Gorzo et al.

    A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice

    Nat. Med.

    (2017)
  • R.M. Bitencourt et al.

    From an alternative medicine to a new treatment for refractory epilepsies: can cannabidiol follow the same path to treat neuropsychiatric disorders?

    Front. Psychiatr.

    (2021)
  • A.W. Bruijnzeel et al.

    Effects in rats of adolescent exposure to cannabis smoke or THC on emotional behavior and cognitive function in adulthood

    Psychopharmacology (Berl)

    (2019)
  • A.C. Campos et al.

    Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders

    Philos. Trans. R. Soc. B Biol. Sci.

    (2012)
  • M.P. Castelli et al.

    Male and female rats differ in brain cannabinoid CB1 receptor density and function and in behavioural traits predisposing to drug addiction: effect of ovarian hormones

    Curr. Pharmaceut. Des.

    (2014)
  • J.F. Cheer et al.

    Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats

    J. Neurosci.

    (2004)
  • Cited by (0)

    View full text